These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38742779)

  • 1. Efficacy and Safety of Oral Alendronate Treatment in Children and Adolescents with Osteoporosis.
    Unal E; Abaci A; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):523-528. PubMed ID: 38742779
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.
    Martín Siguero A; Áreas Del Águila VL; Franco Sereno MT; Fernández Marchante AI; Pérez Serrano R; Encinas Barrios C
    Farm Hosp; 2015 Nov; 39(6):350-4. PubMed ID: 26618379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease.
    Aggarwal HK; Jain D; Chhabra P; Yadav RK
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2018 Jul; 39(1):5-13. PubMed ID: 30110263
    [No Abstract]   [Full Text] [Related]  

  • 4. A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy.
    Kunisaki C; Tanaka Y; Kosaka T; Miyamoto H; Sato S; Suematsu H; Yukawa N; Sato K; Izumisawa Y; Akiyama H; Taguri M; Yamanaka T; Endo I
    Digestion; 2017; 95(2):162-171. PubMed ID: 28214864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
    Hwang JS; Liou MJ; Ho C; Lin JD; Huang YY; Wang CJ; Tsai KS; Chen JF
    J Bone Miner Metab; 2010 May; 28(3):328-33. PubMed ID: 20012918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.
    Imai K
    Clin Interv Aging; 2013; 8():681-8. PubMed ID: 23766643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In brief: effervescent alendronate.
    Med Lett Drugs Ther; 2012 Oct; 54(1401):84. PubMed ID: 23059422
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
    Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
    Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evidence of alendronate treatment for osteoporosis].
    Harada A
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():337-43. PubMed ID: 18161127
    [No Abstract]   [Full Text] [Related]  

  • 13. Adherence to alendronate in male veterans.
    Hansen KE; Swenson ED; Baltz B; Schuna AA; Jones AN; Elliott ME
    Osteoporos Int; 2008 Mar; 19(3):349-56. PubMed ID: 17898921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract]   [Full Text] [Related]  

  • 15. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
    Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
    Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P; Gamerdinger D; Spieler W; Kann PH; Loeffler H; Articus K; Möricke R; Ziller V
    Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.
    Unal E; Abaci A; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):523-8. PubMed ID: 16759038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 20. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.